Ovarian Cancer Recurrent Clinical Trial
Official title:
Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers
This is a feasibility single-center study to investigate the tolerability, toxicity, quality of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for treatment of recurrent ovarian, peritoneal, and fallopian tube cancers.
Ovarian cancer is the leading cause of gynecological cancer mortality; it is in 75% of cases detected at advanced stages. The standard treatment is cytoreductive surgery with removal of macroscopic tumor, and intravenous chemotherapy. Three randomized trials observed survival gain for ovarian cancer patients that received intraperitoneal chemotherapy after the optimal cytoreduction, however catheter-related complications made the procedure not feasible. A "one-time" hyperthermic intraperitoneal chemotherapy, HIPEC, is an established for peritoneal carcinosis in colorectal cancer, and recently two phase III randomised clinical studies observe survival gain also for ovarian cancer patients after surgery with HIPEC. Here the investigators, plan to investigate the HIPEC procedure following cytoreductive surgery for recurrent ovarian cancer, a progressed disease without any standard treatment established. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06014528 -
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04175470 -
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT03983226 -
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
|
Phase 2 | |
| Recruiting |
NCT05095558 -
Microtransplantation for Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03657966 -
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06102707 -
The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients
|
N/A | |
| Terminated |
NCT03162562 -
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
|
Phase 1 | |
| Withdrawn |
NCT04149145 -
Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT01332656 -
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
|
Phase 2 | |
| Completed |
NCT01111903 -
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03734692 -
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03827837 -
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT05990192 -
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
|
Phase 2 | |
| Completed |
NCT01485848 -
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT03681548 -
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
|
Phase 1 | |
| Recruiting |
NCT04072263 -
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
|
Phase 1/Phase 2 |